Paracervical Block for Pain Control With Osmotic Dilator Placement

May 21, 2019 updated by: Lisa Bayer, University of California, San Diego

Paracervical Block for Pain Control During Osmotic Dilator Placement: a Randomized Controlled Trial

Cervical dilators are frequently used for preparation prior to second trimester surgical abortion. While their use decreases complications associated with surgical abortion, their placement is often uncomfortable for the patient. Currently there are no proven methods for reducing pain during osmotic dilator placement. The use of numbing medication around the cervix (paracervical block) may decrease this placement pain.

Study Overview

Detailed Description

It is estimated that 1.21 million abortions were performed in 2008. Of these, approximately 11% occurred in the second trimester and 1.4% occurred after 21 weeks gestation. In the United States, dilation and evacuation (D&E) is the most common method of terminating a second trimester pregnancy with greater than 98% of second trimester abortions occurring by D&E.

Pre-procedure cervical preparation decreases the incidence of complications associated with D&E. Cervical dilators are often used prior to second trimester D&Es to aid in softening and dilating the cervix. Typically, dilator placement occurs the day of the D&E or 1-2 days prior and oftentimes occurs in an outpatient clinic setting without anesthesia readily available. Many women experience moderate to severe discomfort with osmotic dilator insertion. Providers use various methods to minimize this discomfort including paracervical block (PCB), non-steroidal anti-inflammatory medications (NSAIDs), anxiolytics and narcotics. In particular, PCB and NSAIDs are readily available in the clinic setting and can be used for this purpose. There is, however, no data to support their efficacy in ameliorating the pain of dilator insertion.

Paracervical blocks are used commonly to decrease pain in abortion procedures and other gynecological procedures. The PCB is thought to work primarily by blocking pain conduction via Frankenhauser's plexus. As such, their effect may be most important in relieving the pain associated with cervical dilation. In a recent randomized control trial, PCB prior to first trimester surgical abortion was found to significantly reduce pain with cervical dilation and uterine aspiration. Since osmotic dilator placement primarily involves cervical manipulation and dilation, PCB may provide some pain relief over placebo. The research team proposes a randomized controlled trial to evaluate the efficacy of a PCB in decreasing pain associated with osmotic dilator placement. This trial will also provide information about the degree of pain that women experience during osmotic dilator placement; information not previously known.

Study Type

Interventional

Enrollment (Actual)

14

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • San Diego, California, United States, 92101
        • Planned Parenthood of the Pacific Southwest: First Avenue Family Planning Michelle Wagner Center
      • San Diego, California, United States, 92103
        • UCSD Medical Offices South: Women's Health Services

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • voluntarily seeking surgical pregnancy termination
  • gestational age on day of study 14w0d to 23w6d confirmed by pelvic ultrasound with a viable pregnancy (no fetal demise diagnosed)
  • eligible for second trimester D&E
  • having osmotic dilators placed for cervical preparation the day prior to D&E
  • able and willing to give informed consent and agree to terms of the study
  • able to speak and read English or Spanish

Exclusion Criteria:

  • took any prescription or illegal drugs 24 hours prior to the appointment
  • drank alcohol 12 hours prior to the appointment
  • took any over the counter pain medications 12 hours prior to the appointment other than the standard 800mg of Ibuprofen
  • contraindications to osmotic dilators
  • allergic reaction or hypersensitivity to NSAIDs or lidocaine
  • untreated acute cervicitis or pelvic inflammatory disease
  • weight <100 pounds

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Sham Comparator: Sham Group

This non-intervention group will receive the sham paracervical block. This intervention will include

  • Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement
  • Local anesthetic for tenaculum placement
  • Sham Paracervical Block done with capped spinal needle
  • osmotic dilators placed in the usual fashion
  • postprocedural assessment
2 mL of buffered Lidocaine injected superficially at anterior lip of cervix in 12 o'clock position Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate
Over 60 seconds, without moving the tenaculum, a capped needle gently touches the vaginal sidewall at the level of the external os at 4 and 8 o'clock positions

Osmotic dilators will be placed in the usual fashion with a combination of Dilapan-S and laminaria per clinician preference

Drugs:

Dilapan-S is a hygroscopic cervical dilator made of a patented hydrogel called AQUACRYL. It is a rigid hydrophilic stick that increases in volume by absorbing fluids and comfortably dilating the cervix.

Laminaria is an herbal medicine used to induce labor and abortion. The dried stem of Laminaria mechanically dilates the cervical opening by absorbing water and swelling to several times its original diameter.

15 minutes after procedure, subjects will complete a questionnaire that collects information about pain, negative symptoms, and assessment of how effective their pain management was.
800 mg Ibuprofen taken before dilator placement
Experimental: Paracervical Block Group

This intervention group will receive the paracervical block. This intervention will include

  • Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement
  • Local anesthetic for tenaculum placement
  • 18 ml 1% buffered lidocaine Paracervical Block
  • osmotic dilators placed in the usual fashion
  • postprocedural assessment
2 mL of buffered Lidocaine injected superficially at anterior lip of cervix in 12 o'clock position Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate

Osmotic dilators will be placed in the usual fashion with a combination of Dilapan-S and laminaria per clinician preference

Drugs:

Dilapan-S is a hygroscopic cervical dilator made of a patented hydrogel called AQUACRYL. It is a rigid hydrophilic stick that increases in volume by absorbing fluids and comfortably dilating the cervix.

Laminaria is an herbal medicine used to induce labor and abortion. The dried stem of Laminaria mechanically dilates the cervical opening by absorbing water and swelling to several times its original diameter.

15 minutes after procedure, subjects will complete a questionnaire that collects information about pain, negative symptoms, and assessment of how effective their pain management was.
800 mg Ibuprofen taken before dilator placement
18 mL of buffered Lidocaine is slowly injected into the vaginal fornices and equally distributed at 4 and 8 o'clock. The injection is continuous from superficial to deep (3cm) to superficial (injecting with insertion and withdrawal) Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain at Time of Osmotic Dilator Placement
Time Frame: Within 5 minutes of PCB or sham procedure
Measure of distance (mm) from the left ("no pain") on the 100-mm visual analog scale (VAS - reflecting magnitude of pain) recorded at time immediately after osmotic dilator placement. 0 mm=No Pain and 100 mm= worst possible pain. A higher score indicates a higher level of pain.
Within 5 minutes of PCB or sham procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain With Paracervical Block or Sham
Time Frame: Within 5 minutes after baseline
Measure of distance (mm) from the left ("no pain") on the 100-mm visual analog scale (VAS - reflecting magnitude of pain) recorded at time immediately after last injection for paracervical block OR script for sham injection. 0 mm=No Pain and 100 mm= worst possible pain. A higher score indicates a higher level of pain.
Within 5 minutes after baseline
Reported Pain at Baseline
Time Frame: Baseline, just prior to PCB or sham procedure
Measure of distance (mm) from the left ("no pain") on the 100-mm visual analog scale (VAS - reflecting magnitude of pain) of pain recorded at baseline prior to the paracervical block or sham block procedure. 0 mm=No Pain and 100 mm= worst possible pain. A higher score indicates a higher level of pain.
Baseline, just prior to PCB or sham procedure
Pain With Overall Dilator Placement
Time Frame: 15 minutes after dilator placement
Measure of distance (mm) from the left ("no pain") on the 100-mm visual analog scale (VAS - reflecting magnitude of pain) recorded 15 minutes after osmotic dilator placement. mm=No Pain and 100 mm= worst possible pain. A higher mean score indicates a higher level of pain experienced at this time point.
15 minutes after dilator placement

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Lisa Bayer, MD MPH, UCSD Department of Reproductive Medicine
  • Principal Investigator: Kelly Culwell, MD MPH, Planned Parenthood of the Pacific Southwest

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 2, 2015

Primary Completion (Actual)

August 25, 2015

Study Completion (Actual)

August 25, 2015

Study Registration Dates

First Submitted

January 29, 2015

First Submitted That Met QC Criteria

January 29, 2015

First Posted (Estimate)

February 3, 2015

Study Record Updates

Last Update Posted (Actual)

June 11, 2019

Last Update Submitted That Met QC Criteria

May 21, 2019

Last Verified

May 1, 2019

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pain

Clinical Trials on Local anesthetic for tenaculum placement

3
Subscribe